Victoria Johnson

Mease went over research initiatives including the ARGO, AXIS, and STAR studies.

The MTX + HCQ group had a higher, but not statistically significant, incidence rate of TEAEs than the monotherapy group.

The rheumatology month in review emphasize's bimekizumab's efficacy in treating PsA and new risk factors and mitigators for developing gout or hyperuricemia.

Investigators noted that a formal independent validation cohort needs to be developed in order to realize the full potential of the human model.

Investigators identified 6 themes during semistructed interviews that contributed to and described the experience of people with gout.

Researchers identified 2 genes associated with increased risk and 3 associated with decreased risk.

Mease discussed data supporting FDA approval for the indications in Fall 2024.

Those with limited health literacy had higher disease activity and more SLE damage.

Dialysis efficiency was similar between the ULT group and the no ULT group.

Lengths of stay, total cost, and hospital mortality rates were similar between patients with and without rheumatoid arthritis.

Investigators found that 107 metabolites were associated with the incidence of hospitalized gout.

Investigators also found that bDMARDs were used more often by patients with early-onset rheumatoid arthritis than by patients with late-onset.

Molybdenum’s antioxidative properties may help reduce systemic inflammation, ROS, and uric acid levels.

Productivity improved in patients with IA after starting treatment.

Other recent research found that having osteoarthritis increased the risk of developing carpal tunnel syndrome.

Higher risk associations also included being a current smoker and socioeconomic deprivation.

Another recent study found that the risk of joint damage and gout flares were most important to patients when considering ULT discontinuation.

More patients also switched from combination therapy to monotherapy at any time in both analyzed database populations.

Around 20% of participants had ultrasound evidence of at least 1 active enthesitis, and 15.7% had ultrasound signs of at least 1 active synovitis at examination.

Each unit increase in TyG index was associated with 40% higher odds of gout.

A separate paper also found that the overall risk of serious infection was low in new users of targeted therapy.

Both treatment arms experienced significant improvements in measured parameters from baseline, although these were not all statistically significant.

A retrospective analysis compared data from the BE OPTIMAL and BE COMPLETE trials with data from pivotal trials of the IL-23–targeting therapies.

The study was not adequately powered to assess a significant association with cancer mortalities.

Adalimumab-aaty was FDA approved on May 23, 2023, and became commercially available in the US on July 2, 2023.

Similar trends were seen in study participants that transitioned from receiving placebo to bimekizumab after study week 16.

Adjusted analyses reveal a statistically significantly higher prescription medication cost in patients with RA compared to those without.